Altern Ther Health Med. 2024 Jul 19:AT10280. Online ahead of print.
ABSTRACT
OBJECTIVE: The study aimed to investigate the factors influencing the efficacy of Shenqi Yanshen Granule in ameliorating proteinuria among nephrotic syndrome patients in renal function stages 1-3.
METHODS: 100 patients with nephrotic syndrome and renal function stages 1-3, treated at our hospital from May 2021 to March 2023 were enrolled. All patients received Shenqi Yanshen granule treatment. The patients were divided into the control group (n = 68, with proteinuria reduction of ≥50%) and the observation group (n = 32, with proteinuria reduction of <50% or increased proteinuria) at 24 hours after treatment. Clinical data, proteinuria levels at 24 hours after treatment, renal function indices, and mean blood pressure were statistically compared. The efficacy of Shenqi Yanshen Granule in treating proteinuria and factors influencing the efficacy was assessed using multiple logistic regression.
RESULTS: The observation group had a higher average age and duration of disease compared to the control group (P < .05). Upon treatment, proteinuria decreased in both groups (P < .05), with higher levels in the observation group than in the control group. Post-treatment, serum creatinine levels decreased and GFR increased in the control group (P < .05), while the serum creatinine level increased and GFR decreased in the observation group (P < .05). Mean blood pressure decreased in both groups post-treatment (P < .05). The observation group exhibited lower rates of remarkable and effective outcomes and higher rates of general effective and ineffective outcomes (P < .05). Logistic regression analysis highlighted age, severity of nephropathy, underlying conditions, lifestyle, and pre-treatment proteinuria as significant factors influencing the impact of Shenqi Yanshen Granule on proteinuria in patients with nephrotic syndrome (P < .05).
CONCLUSION: Shenqi Yanshen Granule proves to be a potent intervention for reducing proteinuria in patients with nephrotic syndrome. Notably, age and disease severity emerge as pivotal determinants of drug efficacy.
PMID:39038363
